Saniona received approximately USD $2.9 million (SEK 24.2 million) upfront payment in connection with Cadent Therapeutics transaction
January 25, 2021 08:00 ET
|
Saniona AB
PRESS RELEASE January 25, 2021 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced it received approximately USD $2.9 million (SEK 24.2...
Praxis Precision Medicines Receives Rare Pediatric Disease and Orphan Drug Designations for Severe Pediatric Epilepsy Programs
January 07, 2021 08:00 ET
|
Praxis Precision Medicines, Inc
FDA grants RPD and ODD for PRAX-222 for treatment of SCN2A-DEE FDA grants RPD for PRAX-562 for treatment of SCN2A-DEE and SCN8A-DEE CAMBRIDGE, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Praxis...
Saniona deltar på tre kommande investerarkonferenser
January 07, 2021 08:00 ET
|
Saniona AB
PRESSMEDDELANDE 7 januari 2021 Saniona (OMX: SANION), ett biofarmaceutiskt företag med klinisk utveckling fokuserad på sällsynta sjukdomar, meddelar idag att Rami Levin, Sanionas koncernchef och VD,...
Saniona to present at three upcoming investor conferences
January 07, 2021 08:00 ET
|
Saniona AB
PRESS RELEASE January 7, 2021 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that Rami Levin, President and Chief Executive Officer of...
Inozyme Pharma Announces Authorization to Proceed in U.S. and U.K. with Phase 1/2 Clinical Trial of INZ-701 for the Treatment of ENPP1 Deficiency
January 04, 2021 06:00 ET
|
Inozyme Pharma Inc.
– U.S. Food and Drug Administration cleared Investigational New Drug Application – – United Kingdom Medicines and Healthcare Products Regulatory Agency authorized Clinical Trial Application – –...
Saniona förstärker ledningsgruppen med en Chief Legal Officer och en Chief Technical Operations Officer
December 21, 2020 08:00 ET
|
Saniona AB
PRESSMEDDELANDE 21 december 2020 Saniona (OMX: SANION), ett biofarmaceutiskt företag med klinisk utveckling fokuserad på sällsynta sjukdomar, meddelar idag att ledningsgruppen utökas ytterligare...
Saniona Appoints Chief Legal Officer and Chief Technical Operations Officer to Its Executive Team
December 21, 2020 08:00 ET
|
Saniona AB
PRESS RELEASE December 21, 2020 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced the further expansion of its executive team with the...
Saniona minskar sin ägarandel i Scandion Oncology till under 5 procent som ett resultat av Scandions framgångsrika företrädesemission
December 16, 2020 02:00 ET
|
Saniona AB
PRESSMEDDELANDE 16 december 2020 Saniona minskar sin ägarandel i Scandion Oncology till under 5 procent som ett resultat av Scandions framgångsrika företrädesemission Saniona (OMX: SANION), ett...
Saniona’s Ownership Stake in Scandion Oncology Reduced Below 5% Following Scandion’s Successful Rights Issue
December 16, 2020 02:00 ET
|
Saniona AB
PRESS RELEASE December 16, 2020 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced the reduction of its ownership stake in Scandion Oncology...
Travere Therapeutics Announces Completion of Patient Enrollment in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis
November 30, 2020 16:05 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Travere Therapeutics (NASDAQ: TVTX) today announced completion of patient enrollment in the Phase 3 DUPLEX Study. The pivotal DUPLEX Study is evaluating...